LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) announced its inclusion in the Russell Microcap® Index, effective after the close of U.S. markets on June 26, 2026, with the reconstituted index taking effect at the opening of trading on June 29, 2026. The company stated that being added to this widely followed benchmark is expected to increase its visibility among institutional investors and investment products that track Russell indexes.
The milestone reflects progress under LIXTE's new leadership and strategic direction, supporting its efforts to build a platform focused on AI energy infrastructure equipment and services. The Russell Microcap Index is reconstituted annually and measures the performance of smaller publicly traded U.S. companies. Inclusion in such an index often leads to increased demand from index funds and exchange-traded funds (ETFs) that track it, potentially boosting liquidity and shareholder base.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company. Its lead compound, LB-100, is a first-in-class clinical PP2A inhibitor that has shown tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to enhance chemotherapies and immunotherapies. The company is also developing electronically controlled proton therapy systems through its wholly owned subsidiary, Liora Technologies Europe Ltd., with its proprietary LiGHT System believed to offer advantages over current proton therapy technologies.
The addition to the Russell Microcap Index marks a significant step for LIXTE as it seeks to broaden its investor base and capitalize on its strategic pivot. The company's focus on AI energy infrastructure equipment and services represents a diversification from its core oncology and proton therapy businesses. For more details, the full press release is available at https://ibn.fm/r6l81.
Investors can find the latest news and updates relating to LIXT in the company's newsroom at https://ibn.fm/LIXT. The inclusion in the Russell Microcap Index is expected to provide LIXTE with enhanced visibility and credibility in the financial markets, potentially attracting more institutional interest and supporting its growth initiatives.
